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disease  curable? It is resectable, but whether such a local 
 approach substantially impacts on patient outcome we do not 
know!
Should we be more aggressive in primarily metastasized 
patients with regard to local therapy? Until recently, the 
 oncology community had been influenced by the growing 
 retrospective data pool concerning locoregional treatment in 
primary metastatic breast cancer. A meta-analysis of these 
data showed a more than doubled 3-year survival probability 
if the primary tumor was removed [5]. However, these appar-
ently convincing data were contradicted by 2 prospective tri-
als presented at the San Antonio Breast Cancer Symposium 
in December 2013. These data are presented and discussed by 
Steffi Hartmann and her colleagues [6] in this issue of Breast 
Care. Both prospective studies, well designed and fully re-
cruited with an appropriate patient number, did not show any 
survival advantage by removing the primary tumor in stage IV 
disease. The authors also quote the caveats generated by 
older biological hypotheses: removing the primary tumor 
could even promote the growth of distant metastases, espe-
cially in women with multiple distant metastases [7]. They 
conclude that at the moment, breast surgery for these patients 
should not be offered as a routine practice outside clinical 
 trials. The surgeon’s scalpel may be ready to remove the 
tumor, however, this cut may be even shorten a patient’s life! 
Should we monitor palliative treatment more intensively? 
Standard monitoring comprises imaging including computed 
tomography and magnetic resonance tomography, and moni-
toring tumor markers, such as Ca 15-3 or CEA. Treatment for 
metastases normally is continued until response or resistance 
can be shown by shrinkage or growth of the metastases. How-
ever, serial detection of circulating tumor cells (CTC) could 
be a tool for better guiding potentially toxic therapies accord-
ing to response prediction. Unfortunately, current evidence 
does not support a survival improvement in patients treated 
according to this model. Alunni-Fabbroni and colleagues [8] 
conclude that to date CTC should only be used within clinical 
studies. Thus, precision of medical treatment sometimes is not 
as easy as a knife’s cut!
Current data from epidemiology shows that early breast 
cancer has become a curable disease. The mortality is declin-
ing substantially, less than 20% of patients diagnosed with 
breast cancer today will die from the disease [1–3]. Overall 
survival of > 90% seems feasible in operable breast cancer. 
Even the survival of patients with locally advanced disease 
has improved by more than 20% over the last 20 years. Fewer 
patients will experience metastases and it almost seems that 
metastatic breast cancer has stepped into the background. 
Consequently, we observe that less metastatic breast cancer 
patients than ever can be accrued for clinical trials.
Seeing so many optimistic results from early disease, it is 
quite understandable that patients, as well as their physicians, 
hope that also metastatic disease will become curable rather 
than merely well treatable. And sometimes they act as if it 
were already curable even without having sufficient evidence. 
Thus, the content of this issue of Breast Care is focused on 
interventions in metastatic breast cancer with a curative 
intent.
Is oligometastatic disease curable? Olivia Pagani and her 
colleague [4] discuss situations in which radical surgical or 
 radiotherapeutical approaches to treat metastases may be 
 applied with a curative intent. Some patients present with 
only a single or very few metastases. Quite understandably, 
they often ask to have them completely removed, surgically or 
by radiotherapy. The authors correctly state that unfortu-
nately only retrospective data support such a procedure and 
apparently favorable results of ‘radical’ local therapy for lim-
ited metastatic disease may simply be the effect of a selection 
bias. Although in some patients such approaches may be 
 helpful, this should not be generalized. The authors conclude 
that prospective clinical trials are required and that primary 
aims of such trials need to be carefully selected; moreover, 
maintaining quality of life and functional status may some-
times be more important than just small differences in sur-
vival. It is currently not clear, whether ‘radical’ local therapy 
for oligometastases is beneficial. Therefore, this approach 
should be confined to individual cases after thorough multi-
disciplinary discussion of the pros and cons. Is oligometastatic 
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In summary, in treatment of metastatic breast cancer, with 
our considerations and decisions we often teeter on a knife’s 
edge. Yet, most frequently we need to admit that we can only 
achieve palliation, rarely we can realistically hope for cure. It 
is our responsibility to explain this realistic truth to our 
patients.
As shown above, there are more questions than answers in 
evidence-based treatment of patients with metastatic breast 
cancer. Thus, we appreciate and support the efforts that were 
undertaken to establish an international consensus confer-
ence on diagnosis and treatment of metastatic breast cancer 
(Advanced Breast Cancer Symposium in Lisbon ABC 2, 2013 
[9]). There are still needs and new options for improving 
treatment in these patients.
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